Biomaterials for Regenerative Medicine and Nucleic Acid Delivery
PROJECT COST:
PRIMA CONTRIBUTION:
PROJECT DETAILS:
This project builds on expertise developed at Polytechnique Montréal in the application of a biopolymer for articular tissue repair and the delivery of therapeutic RNA. Two Montréal-based companies, ANRis Pharmaceuticals and Ortho RTI, have recently acquired the commercialization rights and associated intellectual property for these technologies.
To support the development of products based on these innovations, research and development activities will be carried out at Polytechnique Montréal in close collaboration with researchers from industrial partners and external collaborators. This proposal outlines the objectives and methodology for the design, development, and optimization of novel therapeutic products, as well as the preclinical validation of their efficacy in relevant animal models. It also presents the strategy for technology transfer and the scale-up of manufacturing processes in accordance with Good Manufacturing Practice (GMP) requirements.
By the end of the project, we expect to have generated a comprehensive body of data demonstrating the safety and efficacy of Ortho RTI’s products for the treatment of rotator cuff tendon tears and meniscal injuries. For ANRis Pharmaceuticals, the project aims to identify highly efficient kidney-targeted RNA delivery platforms and to assess additional therapeutic applications following intradermal, intratumoral, and intratracheal administration.
In parallel, GMP-compliant manufacturing processes will be established at the 15-50 g production scale, thereby supporting the translation, regulatory advancement, and commercialization of products developed by our industrial partners.
SECTORS:
INDUSTRIAL PARTNERS:
RESEARCH PARTNERS:
